Vir Biotechnology (NASDAQ:VIR) Director Sells $30,240.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the sale, the director owned 21,216 shares in the company, valued at $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vir Biotechnology Stock Up 4.3%

NASDAQ VIR opened at $9.15 on Friday. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $11.66. The firm has a market capitalization of $1.54 billion, a PE ratio of -2.92 and a beta of 1.65. The stock’s 50 day moving average is $9.50 and its 200 day moving average is $8.02.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.84). Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. The firm had revenue of ($0.03) million for the quarter, compared to the consensus estimate of $55.49 million. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. On average, research analysts anticipate that Vir Biotechnology, Inc. will post -1.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Avidity Partners Management LP purchased a new position in shares of Vir Biotechnology in the first quarter worth $8,512,000. Bank of America Corp DE raised its stake in shares of Vir Biotechnology by 3.7% in the first quarter. Bank of America Corp DE now owns 965,814 shares of the company’s stock worth $8,654,000 after purchasing an additional 34,906 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Vir Biotechnology by 47.9% in the first quarter. Janus Henderson Group PLC now owns 54,789 shares of the company’s stock worth $491,000 after purchasing an additional 17,732 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Vir Biotechnology in the first quarter worth $24,593,000. Finally, Amundi raised its stake in shares of Vir Biotechnology by 52.8% in the first quarter. Amundi now owns 15,315 shares of the company’s stock worth $137,000 after purchasing an additional 5,294 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on VIR. Morgan Stanley set a $23.00 target price on Vir Biotechnology in a report on Friday, May 8th. Barclays boosted their target price on Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, February 24th. Raymond James Financial raised Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price on the stock in a report on Tuesday, February 24th. Leerink Partners boosted their target price on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.38.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.